List of Excipients in Branded Drug CABTREO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	CABTREO	clindamycin phosphate/benzoyl peroxide/adapalene	0187-0006	CARBOMER HOMOPOLYMER TYPE C	2040-07-31
Bausch Health US LLC	CABTREO	clindamycin phosphate/benzoyl peroxide/adapalene	0187-0006	POTASSIUM HYDROXIDE	2040-07-31
Bausch Health US LLC	CABTREO	clindamycin phosphate/benzoyl peroxide/adapalene	0187-0006	PROPYLENE GLYCOL	2040-07-31

Last updated: August 30, 2026

Cabtreo is a fixed-dose topical acne product with a commercially useful excipient platform: an aqueous gel containing adapalene 0.1%, benzoyl peroxide 2.5%, and clindamycin phosphate equivalent to 1.2% clindamycin. The principal opportunity is not a novel inactive ingredient. It is control of drug solubilization, suspension stability, skin tolerability, preservative performance, packaging, and generic substitution barriers in a three-active formulation.

Cabtreo's excipient strategy supports premium prescription positioning, lifecycle reformulation, alternative delivery systems, and potential licensing to generic or specialty dermatology companies. The main competitive threat is an ANDA product that matches the active concentrations while improving texture, irritation, packaging, or price.

Cabtreo Excipient Strategy, Formulation Patents, Generic Risk, and Commercial Opportunities

What is Cabtreo and which excipients does it contain?

Cabtreo is a prescription topical gel approved by the U.S. Food and Drug Administration in October 2023 for the topical treatment of acne vulgaris in patients 12 years of age and older. It combines three established acne actives in one product:

Attribute	Cabtreo
Active ingredients	Adapalene 0.1%, benzoyl peroxide 2.5%, clindamycin phosphate equivalent to 1.2% clindamycin
Dosage form	Topical gel
Route	Cutaneous
Applicant/marketer	Ortho Dermatologics, a division of Bausch Health
NDA	NDA 217806
FDA approval	October 2023
Target population	Patients 12 years and older with acne vulgaris
Regulatory pathway	Full NDA approval
Commercial category	Prescription fixed-dose combination acne therapy

The FDA label identifies the following inactive ingredients:

• Carbomer homopolymer type B
• Glycerin
• Isopropyl myristate
• Methylparaben
• Poloxamer 124
• Propylene glycol
• Purified water
• Sodium hydroxide

The formulation uses a conventional dermatology excipient architecture. Water and polyols provide the continuous phase and humectancy. Carbomer creates gel viscosity. Sodium hydroxide adjusts pH and neutralizes the carbomer. Isopropyl myristate functions as an emollient and skin-feel modifier. Poloxamer 124 supports wetting and interfacial behavior. Methylparaben provides preservation support. The formulation must accommodate three actives with different chemical and physical properties without compromising stability or application performance. (U.S. Food and Drug Administration, 2023)

Why is Cabtreo's excipient system technically difficult?

Cabtreo combines a retinoid, an oxidizing antimicrobial, and an antibiotic in a single topical vehicle. That combination creates several formulation constraints.

Adapalene dispersion and skin delivery

Adapalene is poorly water-soluble and generally requires controlled dispersion or solubilization strategies. Particle size, wetting, crystal growth, and uniformity affect dose delivery and local tolerability. Carbomer viscosity helps suspend dispersed material and limits settling during storage.

An alternative formulation could use smaller particles, a different polymer network, a lipid-based vehicle, or a solvent system that changes adapalene deposition in the stratum corneum. These changes could support differentiated claims relating to spreadability, reduced residue, or improved tolerability.

Benzoyl peroxide stability

Benzoyl peroxide is chemically reactive and can degrade under unfavorable conditions involving heat, light, metals, pH, or incompatible packaging. The formulation must maintain potency while limiting irritation and avoiding unwanted oxidation of other formulation components.

Packaging is part of the excipient strategy. An airless pump, opaque tube, or other low-oxygen container can reduce exposure to environmental stress. A formulation company that controls both vehicle and package may have a stronger product platform than one that changes excipients alone.

Clindamycin compatibility

Clindamycin phosphate is water-soluble but can be affected by pH, ionic environment, preservatives, and interactions with polymers or other actives. The formulation must maintain chemical stability while delivering a consistent dose across the product's shelf life.

The presence of an antibiotic also creates a commercial requirement for responsible use. A reformulation that improves adherence while preserving the fixed-dose combination could have value, but a product that increases unnecessary antibiotic exposure could face commercial and regulatory resistance.

Skin tolerability and adherence

Adapalene and benzoyl peroxide can cause erythema, dryness, scaling, burning, and irritation, particularly during treatment initiation. Excipients influence these effects through hydration, occlusivity, solvent exposure, spreadability, and drug release.

Glycerin and propylene glycol can support hydration and drug delivery, but polyols may also affect irritation in sensitive users. Isopropyl myristate can improve glide and emolliency, although its sensory profile and acne-related consumer perception require testing. A competing vehicle could target lower sting, faster absorption, lower tack, or reduced whitening.

What commercial opportunities exist for Cabtreo excipients?

The strongest commercial opportunities are in differentiated vehicles and supply-chain control rather than commodity excipient substitution.

Premium reformulation

A reformulated Cabtreo-type product could target:

• Lower irritation during the first weeks of treatment
• Reduced greasiness and tack
• Faster drying
• Lower visible residue
• Improved compatibility with cosmetics and sunscreen
• Better dosing from a pump or metered dispenser
• Longer in-use stability
• Reduced preservative exposure
• Improved suitability for sensitive or darker skin types

These attributes can support prescription switching, specialty dermatology promotion, and potentially a new NDA or supplemental regulatory strategy, depending on the nature of the change.

Excipient supplier partnerships

Suppliers can create value by offering qualified systems rather than individual ingredients. Relevant partnership areas include:

• High-purity carbomer grades with controlled rheology
• Low-peroxide or peroxide-compatible excipients
• Preservative systems compatible with benzoyl peroxide
• Skin-feel modifiers with low comedogenicity concerns
• Airless packaging and low-oxygen dispensing systems
• Particle-engineering platforms for adapalene
• Analytical methods for peroxide, clindamycin, and adapalene stability
• Scale-up support for semisolid manufacturing

A supplier with demonstrated compatibility data can become embedded in the product's development history. That position may create switching costs even when the underlying excipient is not patent protected.

Generic drug development

Generic manufacturers have a direct opportunity to develop a Cabtreo-equivalent topical product through the ANDA pathway. The most commercially attractive formulation would match the active concentrations while improving cost, manufacturability, and patient usability.

The critical development risks include:

1. Demonstrating qualitative and quantitative sameness for inactive ingredients where required.
2. Establishing equivalent product performance.
3. Matching physical characteristics such as viscosity, pH, particle size, globule or droplet distribution, and drug uniformity.
4. Demonstrating comparable in vitro release and permeation behavior.
5. Managing benzoyl peroxide degradation during manufacturing and storage.
6. Designing a package that preserves stability and delivers reproducible doses.

FDA's topical generic framework allows certain products to rely on comparative in vitro and in vivo evidence rather than conventional clinical endpoint trials, but the evidence package depends on the dosage form and applicable product-specific guidance. (U.S. Food and Drug Administration, 2022)

What formulation patents may protect Cabtreo?

Cabtreo's commercial protection can arise from several layers:

Protection layer	Potential subject matter	Relevance
Active-ingredient patents	Adapalene, benzoyl peroxide, or clindamycin use claims	Mostly mature or expired for the individual actives
Combination patents	Co-formulation of the three actives	May affect ANDA timing and Paragraph IV risk
Formulation patents	Vehicle composition, pH, viscosity, particle distribution, stability	Can create product-specific barriers
Method-of-use patents	Treatment of acne with the fixed-dose combination	May support carve-outs or litigation
Packaging patents	Airless, metered, oxygen-limiting, or stability-enhancing packages	Can limit commercial replication
Manufacturing patents	Mixing sequence, particle processing, deaeration, or filling	May be difficult to detect from the finished product
Trademark protection	CABTREO brand	Protects branding, not formulation chemistry

The decisive source for current U.S. patent coverage is the FDA Orange Book and the relevant patent documents. A formulation patent is more commercially important than an expired active-ingredient patent if it claims the approved product's specific composition or a method that an ANDA applicant cannot easily avoid.

Excipients themselves rarely provide meaningful exclusivity. Protection depends on the claimed combination, concentration ranges, functional results, processing steps, or package interaction. A broad claim covering "a gel comprising adapalene, benzoyl peroxide, clindamycin, carbomer, and a polyol" would face greater validity and design-around pressure than a narrower claim tied to demonstrated stability or a specific microstructure.

When does Cabtreo lose exclusivity?

Cabtreo's regulatory exclusivity and patent exclusivity are separate.

FDA exclusivity

Because Cabtreo is a new fixed-dose combination of previously known active ingredients, its exclusivity profile depends on the FDA's determination of the qualifying new clinical investigations supporting approval. A three-year period of exclusivity is the relevant statutory framework for certain applications containing new clinical investigations essential to approval. That period generally restricts approval of an ANDA or certain 505(b)(2) applications relying on the protected conditions of approval, but it does not create the same broad barrier as five-year new chemical entity exclusivity. (U.S. Food and Drug Administration, 2023; U.S. Code, 21 U.S.C. § 355)

The practical implication is that regulatory exclusivity alone is unlikely to protect Cabtreo from long-term generic competition. Patent listings and litigation timing will be more important.

Patent expiry

The applicable Cabtreo patent expiration dates must be read from the current Orange Book listing and the underlying patent records. Any patent term adjustment, patent term extension, pediatric extension, terminal disclaimer, or later listing can affect the effective barrier date.

For commercial planning, the relevant dates are:

1. FDA exclusivity expiry.
2. Earliest permissible ANDA approval date.
3. Paragraph IV notice date.
4. Patent litigation filing deadline.
5. Statutory 30-month stay, if triggered.
6. Patent expiry after any adjustment.
7. Potential first-filer 180-day generic exclusivity.

What is the Orange Book status of Cabtreo?

Cabtreo is an NDA product subject to Orange Book analysis. The Orange Book can identify listed patents and regulatory exclusivity associated with NDA 217806. A generic sponsor evaluating Cabtreo must review the active listing, patent-use codes, expiration dates, and any later FDA updates rather than relying on the product label alone. (U.S. Food and Drug Administration, n.d.)

For the reference product sponsor, Orange Book listing strategy matters because:

• A listed formulation patent can trigger Paragraph IV litigation.
• A method-of-use patent may allow a generic label carve-out.
• An incorrectly broad use code may be challenged.
• A late-listed patent can affect timing but may not recreate an expired exclusivity period.
• A patent not listed in the Orange Book may still be enforceable, but it does not provide the same ANDA-related litigation mechanism.

Which companies are challenging Cabtreo?

Cabtreo is exposed primarily to generic dermatology companies, not biosimilar developers. The product is a small-molecule topical combination, so the relevant competitors would file ANDAs or, in some cases, 505(b)(2) applications.

Potential competitor groups include:

• Large generic manufacturers with topical manufacturing capacity
• Dermatology-focused generic companies
• Contract development and manufacturing organizations
• Private-label pharmaceutical companies
• Firms acquiring rights to approved topical acne products

Public identification of a specific Cabtreo Paragraph IV challenger depends on FDA filings, litigation complaints, and company disclosures. A generic sponsor may also pursue a non-infringing formulation that avoids the need for a public challenge to every listed patent.

What generic launch risks exist for Cabtreo?

The most likely launch scenarios are:

Scenario	Timing profile	Commercial effect
No viable Paragraph IV challenge	After relevant patent barriers	Delayed generic entry
Paragraph IV challenge with settlement	Date determined by agreement	Controlled or staged competition
Court win for generic	Potential pre-expiry launch	Rapid price erosion
Court win for patent holder	Launch delayed until patent expiry	Continued branded pricing
Non-infringing formulation	Depends on regulatory review	May avoid some patent claims
505(b)(2) reformulation	Potentially differentiated product	Higher development cost, broader claims

Topical generics can create substantial substitution pressure because prescribers and payers often treat the active combination as interchangeable in clinical purpose. Cabtreo's commercial defense therefore depends on product experience, patient adherence, payer positioning, pharmacy substitution rules, and any legally enforceable formulation claims.

How strong is the Cabtreo patent estate?

The patent estate should be assessed as moderate rather than automatically strong unless the listed patents claim narrow, validated formulation attributes that are difficult to reproduce.

Strength indicators include:

• Claims directed specifically to the three-active combination
• Narrow stability or degradation limits
• Defined particle-size or microstructure parameters
• Validated performance advantages linked to the claimed excipients
• Manufacturing steps that are difficult to detect or design around
• Package-formulation interaction claims
• Claims supported by comparative data against prior fixed-dose products

Weakness indicators include:

• Broad claims built from well-known dermatology excipients
• Claims that combine mature actives without a clear technical effect
• Easy substitution of carbomer, polyol, preservative, or emollient grades
• Method-of-use claims vulnerable to label carve-outs
• Lack of evidence showing that the excipient combination produces an unexpected result

The formulation's commercial value can exceed the legal strength of any single patent. A stable, cosmetically acceptable, easy-to-use product may retain prescribing share after generic entry, but the brand would face payer pressure and substitution.

How does Cabtreo compare with other acne combination products?

Cabtreo competes with established fixed-dose and sequential regimens.

Product or regimen	Actives	Key commercial distinction
Cabtreo	Adapalene, benzoyl peroxide, clindamycin	Three-active prescription combination
Epiduo Forte	Adapalene, benzoyl peroxide	No antibiotic; avoids antibiotic exposure
Duac and generic equivalents	Clindamycin, benzoyl peroxide	Two-active antibiotic combination
Ziana and generic equivalents	Clindamycin, tretinoin	Retinoid-antibiotic combination
Tactupump and equivalents	Adapalene, benzoyl peroxide	Widely established dual regimen
Separate products	Retinoid, benzoyl peroxide, topical antibiotic	Flexible but less convenient

Cabtreo's commercial advantage is convenience and simultaneous treatment of multiple acne mechanisms. Its disadvantages include higher formulation complexity, potential irritation, antibiotic stewardship concerns, and the possibility that physicians prefer dual therapy or separate products.

What licensing opportunities exist around Cabtreo excipients?

Licensing opportunities fall into four categories.

Vehicle technology licensing

A company could license a lower-irritation gel, emulsion, suspension, or polymer system to the brand owner or a generic sponsor. The value proposition must include comparative stability, sensory, or adherence data.

Packaging licensing

Airless dispensing, metered dosing, and low-oxygen packaging can be licensed independently or bundled with a formulation. Packaging claims may be especially valuable when benzoyl peroxide stability is a central technical problem.

Generic development partnerships

The reference product creates demand for development packages containing:

• Excipient compatibility data
• Analytical methods
• Comparative rheology
• In vitro release testing
• Stability protocols
• Scale-up and filling parameters
• Container-closure qualification

Lifecycle management

The sponsor could pursue a preservative-reduced product, an improved dispenser, a larger commercial presentation, or a reformulation designed for lower irritation. Each option would require assessment of whether the change supports a supplement, a new application, or a different regulatory pathway.

Is there biosimilar risk for Cabtreo?

There is no biosimilar risk in the statutory sense. Cabtreo is not a biologic. Its principal competitive risk is generic ANDA entry and, potentially, a 505(b)(2) topical product.

This distinction matters commercially. Biosimilar entry often involves complex manufacturing and interchangeability considerations. Cabtreo competition will focus instead on pharmaceutical equivalence, topical product performance, formulation similarity, manufacturing scale, pharmacy substitution, and payer contracting.

Key Takeaways

• Cabtreo contains adapalene, benzoyl peroxide, and clindamycin phosphate in a carbomer-based aqueous gel.
• The excipient opportunity is concentrated in stability, tolerability, rheology, skin feel, packaging, and dose consistency.
• Generic manufacturers can target the active combination through the ANDA pathway, subject to Orange Book patents and regulatory requirements.
• Excipients alone rarely create durable exclusivity. Patent value depends on the claimed composition, functional result, process, or package interaction.
• Benzoyl peroxide stability and adapalene dispersion are the main technical barriers.
• A lower-irritation, faster-drying, cosmetic-compatible vehicle could support premium positioning or lifecycle management.
• Cabtreo has generic risk, not biosimilar risk.
• Current patent expiry, Paragraph IV activity, litigation, and settlement exposure must be determined from the live Orange Book, FDA records, PACER, and company disclosures.

FAQs

Can Cabtreo be reformulated without changing its active ingredients?

Yes. A sponsor can change polymers, solvents, humectants, preservatives, particle engineering, pH, packaging, or manufacturing conditions, but the regulatory pathway depends on the extent of the change and whether the product remains pharmaceutically equivalent.

Which Cabtreo excipient is most important for viscosity control?

Carbomer homopolymer type B is the principal gelling polymer identified in the FDA label. Sodium hydroxide neutralizes the polymer and affects the final rheology and pH.

Does Cabtreo's antibiotic component reduce its long-term market potential?

It can. Clindamycin-containing products face antibiotic stewardship concerns and may be displaced by non-antibiotic retinoid and benzoyl peroxide combinations for maintenance therapy.

Can a generic use a different preservative from Cabtreo?

Potentially, subject to applicable sameness requirements, product-specific guidance, safety, stability, preservative effectiveness, and the scope of any patent claims. A different preservative may create a regulatory or formulation-performance issue even when it avoids a patent claim.

What is the strongest commercial defense against a Cabtreo generic?

The strongest defense is a combination of enforceable formulation or package claims, reliable product performance, low irritation, strong patient adherence, payer access, and lifecycle products that offer a clear benefit over a basic active-ingredient copy.

References

1. U.S. Food and Drug Administration. (2022). Draft guidance on topical dermatologic drug products: Development and submission of generic drug products. https://www.fda.gov

2. U.S. Food and Drug Administration. (2023). Cabtreo (adapalene, benzoyl peroxide, and clindamycin phosphate) prescribing information. Ortho Dermatologics/Bausch Health.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Code. (n.d.). 21 U.S.C. § 355: New drugs. Cornell Legal Information Institute. https://www.law.cornell.edu/uscode/text/21/355